Concurrent Chemoradiotherapy of Paclitaxel Liposome and Nedaplatin in the Treatment for Advanced Cervical Squamous Cell Carcinoma

[Purpose]To investigate the efficacy and toxicity of concurrent chemoradiotherapy of paclitaxel liposome and nedaplatin in the treatment for advanced cervical squamous cell carcinoma.[Methods]Twenty-six cases with cervical squamous cell carcinoma stageⅡb～Ⅳa were treated with pelvic cavity external irradiation and high dose rate intracavity brachytherapy,concurrent with chemotherapy(paclitaxel liposome 40mg/m2 with nedaplatin 20mg/m2,once for every week,with total 6 times).The 1-,2-,3-year survival rate and toxicity of chemoradiotherapy were observed.[Results]Complete response(CR)was found in 20 cases(76.9%);partial response(PR),5 cases(19.2%);stable disease(SD),1 case(3.8%);progress disease(PD),none,with response rate of 96.2%(25/26).The 1-,2-,3-year survival rate was 96.2%,88.5%,84.6%,respectively.The toxicities including marrow depression,alopecia and gastrointestinal toxicities were tolerable.The longterm complication of radiotherapy was mild.[Conclusion]Concurrent chemoradiotherapy of paclitaxel liposome and nedaplatin in the treatment for advanced cervical squamous cell carcinoma is effective and tolerable,with good compliance.